Castle Rock Wealth Management LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Castle Rock Wealth Management LLC grew its position in Pfizer Inc. (NYSE:PFEFree Report) by 4.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,503 shares of the biopharmaceutical company’s stock after acquiring an additional 1,327 shares during the quarter. Castle Rock Wealth Management LLC’s holdings in Pfizer were worth $863,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in PFE. Moneta Group Investment Advisors LLC increased its stake in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the period. Norges Bank purchased a new position in Pfizer in the 4th quarter worth about $3,150,472,000. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares in the last quarter. Morgan Stanley boosted its position in Pfizer by 10.3% in the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after buying an additional 7,419,929 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Pfizer during the first quarter worth approximately $311,238,000. 68.05% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $27.94 on Friday. The stock has a market cap of $157.77 billion, a PE ratio of 77.61, a price-to-earnings-growth ratio of 1.26 and a beta of 0.61. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $42.22. The business has a 50-day simple moving average of $27.65 and a 200-day simple moving average of $29.88. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter last year, the company earned $1.14 EPS. The business’s revenue was down 41.3% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Friday, March 1st. Truist Financial cut their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Barclays cut their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. Finally, TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $36.88.

Check Out Our Latest Report on PFE

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.